Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Deep Vein Thrombosis

Despite recent innovations in clot lysis technology, management of acute iliofemoral Deep Vein Thrombosis (DVT) remains a challenge worldwide. Long-term complications of proximal DVT include Postthrombotic Syndrome (PTS), which is characterized by chronic limb heaviness, pain, swelling, paraesthesia, pruritis and pigmentation changes. PTS affects between 23-43% of patients and has been shown to have a significant negative impact on quality of life and a large economic burden on the wider community. Early active treatment to remove thrombus has been shown to result in better outcomes, including lower rates of venous valve dysfunction, recurrent DVT and PTS .The management of acute iliofemoral deep vein thrombosis is constantly evolving. Clot removal techniques, such as surgical thrombectomy and thrombolysis, have been shown to be superior to anticoagulation therapy alone, resulting in decreasing rates of postthrombotic syndrome and DVT recurrence. Nonetheless, there is still a considerable disease burden in the community. In the search for better patient outcomes, we revisit the work of a previous generation of vascular surgeons who created a temporary AVF in combination with a surgical thrombectomy to promote blood flow through the newly re-vascularized vessel. A number of small studies support their work, presenting consistently positive results. We propose that a temporary AVF could be beneficial when used in combination with anticoagulation therapy and CDT or PMCT. A temporary AVF is a simple technique to perform with minimal risk to the patient, and great potential to prevent re-thrombosis and PTS. We believe further investigation is warranted to test this hypothesis. OMICS Group International is one of the leading Open Access Publishing houses, which has around 700+ peer-reviewed journals, 50,000+ editorial board members, and highly qualified, expert reviewers to meet the objectives of the Peer-Review Process. OMICS Group International peer-review policies are highly appreciated, accepted and adaptable to the criteria that have been prescribed by the international agencies such as NIH, PubMed etc. OMICS Group International also organizes 3000+ International Scientific Conferences per year globally. There is a great deal of information out there on scientific topics. However, whether it can be trusted or not is a key issue at present. The main question that often emerges in this aspect is about the review process adopted to screen the articles for publication. One of the most acceptable and proven process adopted in majority reputed international journals is peer reviewing. Benefits of peer-review: • Establishes the legitimacy of exploration based upon the expert information of different specialists in the order, consequently averting adulterated work from being acknowledged within an area of study. • Provides significant criticism with the intention that scientists can revise and enhance their papers before Publication. • Enables Journal editors to select the most important research findings for publication in their journals, based upon the subject, independent reviews of an expert group. • The process of peer review is comprehended and acknowledged by the majority of researchers. The forum includes experts, those who have common area of interest, expertise and experience to evaluate the work to be published. The reviewers will be given priority utmost to reflect the appraisals of a research work and to extract the potentialities of the researcher.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2025

Top